See more : Nouveau Life Pharmaceuticals, Inc. (NOUV) Income Statement Analysis – Financial Results
Complete financial analysis of Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Dye & Durham Limited (DYNDF) Income Statement Analysis – Financial Results
- Genco Shipping & Trading Limited (GNK) Income Statement Analysis – Financial Results
- Z-Work Acquisition Corp. (ZWRK) Income Statement Analysis – Financial Results
- Joy Kie Corporation Limited. (300994.SZ) Income Statement Analysis – Financial Results
- EL.En. S.p.A. (ELEAF) Income Statement Analysis – Financial Results
Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD (300534.SZ)
About Gansu Longshenrongfa Pharmaceutical Industry CO.,LTD
Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd researches, develops, produces, and sells Chinese medicines, health food, and APIs. It offers Yuanhu Analgesic dropping pills, Qiwei Wenyang capsules, Maxing cough capsules, Shuxinning tablets, Panax notoginseng pills, Anti-inflammatory and gallbladder tablets, Children's Qingfei cough tablets, Pediatric Qinggan tablets, Suanzaoren oil dropping pills, Xiaoshuan Tongluo tablets, Xiaoyanlidan tablets, Compound Danshen tablets, and Astragalus Angelica capsules, as well as berberine tannin films. The company also engages in the planting, acquisition, processing, sales, and commercial distribution of Chinese medicinal materials; investment and management of project; and import, sales, logistics, and export of pharmaceutical. Gansu Longshenrongfa Pharmaceutical Industry Co.,Ltd was founded in 2002 and is based in Lanzhou, China.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.08B | 413.25M | 287.81M | 254.90M | 239.00M | 203.17M | 269.59M | 269.68M | 277.36M | 301.58M | 274.89M | 212.68M | 133.37M |
| Cost of Revenue | 386.23M | 249.52M | 195.42M | 171.80M | 148.54M | 116.77M | 181.46M | 171.92M | 169.41M | 200.78M | 202.37M | 161.60M | 101.63M |
| Gross Profit | 693.82M | 163.72M | 92.39M | 83.10M | 90.46M | 86.40M | 88.12M | 97.77M | 107.95M | 100.80M | 72.52M | 51.07M | 31.74M |
| Gross Profit Ratio | 64.24% | 39.62% | 32.10% | 32.60% | 37.85% | 42.53% | 32.69% | 36.25% | 38.92% | 33.42% | 26.38% | 24.01% | 23.80% |
| Research & Development | 30.17M | 9.37M | 6.70M | 5.97M | 7.41M | 6.73M | 6.14M | 6.36M | 10.19M | 9.81M | 8.11M | 0.00 | 0.00 |
| General & Administrative | 16.61M | 8.83M | 4.73M | 2.84M | 2.82M | 3.46M | 3.77M | 2.30M | 2.19M | 1.44M | 3.43M | 12.36M | 10.57M |
| Selling & Marketing | 485.35M | 91.70M | 67.19M | 52.69M | 45.61M | 47.26M | 46.57M | 25.75M | 12.88M | 15.50M | 10.89M | 8.96M | 6.52M |
| SG&A | 568.92M | 100.53M | 71.91M | 55.53M | 48.43M | 50.72M | 50.34M | 28.05M | 15.08M | 16.93M | 14.32M | 21.32M | 17.08M |
| Other Expenses | -206.60K | 5.47M | 4.63M | 1.57M | 500.53K | -8.47K | 36.47K | 4.62M | 2.15M | 3.08M | 2.54M | 1.83M | 2.88M |
| Operating Expenses | 598.62M | 133.83M | 97.54M | 78.24M | 67.15M | 71.47M | 69.47M | 47.84M | 35.14M | 34.97M | 29.74M | 22.53M | 17.98M |
| Cost & Expenses | 984.85M | 383.35M | 292.96M | 250.04M | 215.69M | 188.23M | 250.94M | 219.76M | 204.55M | 235.74M | 232.11M | 184.13M | 119.60M |
| Interest Income | 7.17M | 2.28M | 1.52M | 1.52M | 752.94K | 522.72K | 1.06M | 3.88M | 1.11M | 1.63M | 914.76K | -0.54 | -0.69 |
| Interest Expense | 4.06M | 29.78K | 534.97K | 2.06M | 733.13K | 392.00K | 392.00K | 796.03K | 1.06M | 52.89K | 760.42K | 765.03K | 785.66K |
| Depreciation & Amortization | 26.64M | 27.01M | 22.56M | 19.50M | 19.84M | 17.81M | 15.87M | 6.08M | 3.36M | 3.10M | 2.73M | 1.62M | -370.99K |
| EBITDA | 127.72M | 93.68M | 18.38M | 25.45M | 40.63M | 31.72M | 34.40M | 61.63M | 75.82M | 73.35M | 51.18M | 29.52M | 13.19M |
| EBITDA Ratio | 11.83% | 14.17% | 8.44% | 10.96% | 18.68% | 16.86% | 13.51% | 23.91% | 28.71% | 24.66% | 18.81% | 13.88% | 9.89% |
| Operating Income | 95.20M | 26.73M | -9.38M | 2.25M | 19.53M | 13.52M | 18.08M | 50.11M | 69.82M | 68.00M | 45.70M | 27.90M | 13.56M |
| Operating Income Ratio | 8.81% | 6.47% | -3.26% | 0.88% | 8.17% | 6.66% | 6.71% | 18.58% | 25.17% | 22.55% | 16.62% | 13.12% | 10.17% |
| Total Other Income/Expenses | 1.82M | 3.83M | 4.63M | 1.57M | 500.53K | -8.47K | 36.47K | 4.62M | 2.15M | 3.08M | 2.48M | 1.83M | 2.88M |
| Income Before Tax | 97.02M | 32.20M | -4.75M | 3.82M | 20.03M | 13.52M | 18.12M | 54.73M | 71.96M | 71.08M | 48.17M | 29.73M | 16.43M |
| Income Before Tax Ratio | 8.98% | 7.79% | -1.65% | 1.50% | 8.38% | 6.65% | 6.72% | 20.30% | 25.95% | 23.57% | 17.52% | 13.98% | 12.32% |
| Income Tax Expense | 13.17M | 1.90M | 1.55M | 535.54K | 4.67M | 1.24M | 1.00M | 7.48M | 11.29M | 10.65M | 7.26M | 4.65M | 2.62M |
| Net Income | 61.65M | 25.83M | -9.11M | 1.83M | 12.78M | 12.28M | 17.11M | 47.25M | 60.68M | 60.42M | 40.91M | 25.26M | 13.90M |
| Net Income Ratio | 5.71% | 6.25% | -3.16% | 0.72% | 5.35% | 6.04% | 6.35% | 17.52% | 21.88% | 20.04% | 14.88% | 11.88% | 10.42% |
| EPS | 0.20 | 0.09 | -0.03 | 0.01 | 0.04 | 0.04 | 0.06 | 0.19 | 0.27 | 0.27 | 0.19 | 0.20 | 0.17 |
| EPS Diluted | 0.20 | 0.09 | -0.03 | 0.01 | 0.04 | 0.04 | 0.06 | 0.19 | 0.27 | 0.27 | 0.19 | 0.20 | 0.17 |
| Weighted Avg Shares Out | 303.38M | 303.35M | 303.35M | 303.35M | 303.35M | 303.16M | 303.35M | 246.49M | 227.50M | 227.50M | 209.99M | 128.33M | 79.72M |
| Weighted Avg Shares Out (Dil) | 303.38M | 303.35M | 303.35M | 303.35M | 303.35M | 303.16M | 303.41M | 246.49M | 227.50M | 227.50M | 209.99M | 128.33M | 79.72M |
Source: https://incomestatements.info
Category: Stock Reports